Astrana Health, Inc. is a healthcare management company providing medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative inpatient care sites, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organizations, as well as non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Founded in 1992, it is headquartered in Alhambra, California.
Astrana Health Falls 5.5% on Material Cybersecurity Breach at Subsidiary
Astrana Health shares fell 5.5% in the afternoon session after the healthcare services company disclosed a material cybersecurity incident and data breach at its subsidiary, Astrana Health Management. The cyberattack compounds existing pressure on the stock following a recently announced securities-law investigation into the company's aggressive acquisition strategy, a $545 million related-party loan, and its exposure to 2027 Medicare regulatory changes. Astrana Health is up 31.7% since the beginning of the year, but at $33.22 per share it is still trading 33.3% below its 52-week high of $49.81 from June 2026. The stock has been very volatile, with 28 moves greater than 5% over the last year, and today's drop indicates the market considers the news meaningful but not something that would fundamentally change its perception of the business.
ASTH · Regulation · Negative Astrana Health disclosed a material cybersecurity incident and data breach at its subsidiary, compounding existing regulatory and legal pressures.
Astrana Health Management · Regulation · Negative Astrana Health Management, the subsidiary, suffered a material cybersecurity incident and data breach.
Medicare Advantage Prior Authorization Bill Sinks Insurer Stocks
Bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans, sending several health insurer stocks lower in the morning session. The bill, which received key backing from the American Association of Orthopaedic Surgeons, would require Medicare Advantage health plans to honor initial prior authorizations and strictly prohibit retroactive payment clawbacks. If enacted, the legislation would curtail insurers' ability to adjust or deny reimbursements post-treatment, potentially increasing medical loss ratios and raising administrative compliance burdens across managed care organizations. Among the stocks impacted, Alignment Healthcare fell 12.6%, Clover Health fell 4.8%, Novavax fell 3.6%, and Astrana Health fell 2.7%. Alignment Healthcare's shares are very volatile and have had 23 moves greater than 5% over the last year, and the stock is down 49% since the beginning of the year, trading at $10.32 per share, 58% below its 52-week high of $24.56 from July 2026.
ALHC · Regulation · Negative The Protecting Approved Care Act would bar retroactive clawbacks and force honoring of prior authorizations, raising medical loss ratios for Alignment Healthcare.
ASTH · Regulation · Negative Astrana Health fell as the Medicare Advantage prior-authorization reform bill threatens insurer reimbursement flexibility and raises compliance burdens.
CLOV · Regulation · Negative Clover Health dropped on the bill curtailing Medicare Advantage plans' ability to deny or claw back reimbursements post-treatment.
Astrana Health Q2 Earnings Call: Five Key Analyst Questions
Astrana Health reported second quarter results that beat adjusted EPS and EBITDA estimates but missed on revenue, while management addressed analyst questions on cost trends, Medicare Advantage, Medi-Cal transitions, EBITDA guidance, and AI automation. Revenue came in at $972.5 million versus analyst estimates of $985.4 million, a 48.5% year-on-year increase but a 1.3% miss, while adjusted EPS of $0.80 beat estimates of $0.73 and adjusted EBITDA of $68.89 million beat estimates of $67.93 million. The company reconfirmed full-year revenue guidance of $3.95 billion at the midpoint and EBITDA guidance of $267.5 million at the midpoint, in line with analyst expectations. CEO Brandon Sim attributed operating leverage improvements to the company's proprietary AI-native healthcare operating system and noted that the Prospect Health acquisition contributed to overall performance with gross provider retention above 99%. Analysts from William Blair, Jefferies, Baird, Truist, and KeyBanc Capital Markets asked about commercial cost pressures, Medicare Advantage bid alignment, transitioning Medi-Cal members to full risk, fourth quarter EBITDA seasonality, and the benefits of automated member encounters.
Astrana Health Raises Full-Year 2026 Adjusted EBITDA Guidance After Record Q2 Earnings
Astrana Health Inc reported second-quarter 2026 revenue of $973 million, up 49% year-over-year, and raised its full-year adjusted EBITDA guidance to a range of $255 million to $280 million. Adjusted diluted earnings per share reached a record $0.80, a 45% increase, while adjusted EBITDA rose 43% to $69 million. The company also reaffirmed its full-year revenue guidance of $3.8 billion to $4.1 billion and free cash flow guidance of $105 million to $132.5 million. Net leverage declined to 2.26 times on a trailing 12-month basis, and the company retired $92 million of debt during the quarter. Astrana Health cited broad-based outperformance and continued maturation of full-risk cohorts as drivers for the raised outlook.
Astrana Health Named Profitable Stock to Watch, AT&T and Payoneer Flagged as Sells
StockStory identifies Astrana Health as a profitable stock to target this week, while questioning AT&T and Payoneer. Astrana Health, formerly Apollo Medical Holdings, reported a 55.7% annual revenue growth over the last two years and a 13.2% annual increase in earnings per share over five years, with a forward P/E of 15.3. AT&T faces annual revenue declines of 1.3% over five years and a 7.5% annual drop in earnings per share, trading at 9 times forward P/E. Payoneer's earnings per share growth of 4.8% underperformed its revenue, and its return on equity stands at 7.3%, with shares at 25 times forward P/E.
ASTH · Capital · Positive StockStory highlights Astrana Health's strong revenue and earnings growth and low forward P/E as a profitable stock to watch.
PAYO · Capital · Negative StockStory flags Payoneer as a sell due to weak earnings growth relative to revenue and low return on equity.
T · Capital · Negative StockStory flags AT&T as a sell due to declining revenue and earnings per share over five years.
StockStory picks Cigna and Astrana Health as long-term buys, flags Phibro Animal Health as a sell
StockStory recommends Cigna and Astrana Health for long-term investors while advising against Phibro Animal Health. Cigna is highlighted for its 16.1% annual revenue growth over two years, $277.7 billion in revenue, and 10.9% annual EPS growth over five years. Astrana Health is noted for 55.7% annual revenue growth over two years and 13.2% annual EPS growth over five years. Phibro Animal Health is flagged for its modest $1.5 billion revenue base, projected 2.2% sales growth, and a weak 0.8% free cash flow margin over five years.
Barclays Upgrades Astrana Health to Overweight, Lifts Price Target to $50
Barclays upgraded Astrana Health to Overweight from Equal Weight and raised its price target to $50 from $37. The firm cited materially improved outlook for value-based care, driven by stabilizing cost trends and a more favorable 2027 Medicare Advantage rate outcome. Astrana Health also has room for multiple expansion as it integrates Prospect and accelerates full-risk membership growth. In its fiscal first quarter 2026 results, the company reported total revenue of $965.1 million, up 56% year over year, adjusted EBITDA of $66.3 million, up 82%, and free cash flow of $64.1 million, up 372%.
GoodRx Q1 revenue beats estimates but declines 4.4% year on year
GoodRx reported first-quarter revenues of $194 million, down 4.4% year on year, exceeding analysts' expectations by 4.9%. The company also provided full-year revenue guidance that slightly topped estimates. Among the seven healthcare technology stocks tracked, GoodRx posted the slowest revenue growth, while the group overall beat consensus revenue estimates by 1.6% and issued in-line next-quarter guidance. Omnicell delivered the best performance with revenues of $309.9 million, up 14.9% year on year, and Hims & Hers Health was the weakest, with revenues of $608.1 million missing estimates by 1.4%. Astrana Health achieved the fastest revenue growth at 55.6% year on year, and Tandem Diabetes raised its full-year guidance the most among peers.
United States